Axway named a Leader in the 2023 Gartner® Magic Quadrant™ for API Management
Axway (Euronext: AXW.PA), an API Management leader, today announced that it is positioned by Gartner as a Leader in the 2023 Magic Quadrant™ for API Management for its offering, Amplify API Management.1 The evaluation was based on specific criteria that analyzed the company’s overall completeness of vision and ability to execute. Axway was positioned furthest to the right for Completeness of Vision.
“We are honored to be positioned as a Leader for the eighth time,” said Axway CEO Patrick Donovan. “High-performing organizations are leveraging strong API strategies to drive their growth in a digital world. It isn’t enough to have security, governance and management of APIs alone – you also need a strong platform that unifies what you already have to get your digital products where they can be seen and used.”
“We process up to 120 million requests a day, so we wanted to avoid making any changes to existing API endpoints to minimize the risk for our clients and streamline the migration,” said Willem Salembier, Solution Architect at Smals. “Amplify API Management addresses that requirement perfectly. The Axway solution is extremely flexible, which means we can expose the same functionalities and interfaces while modernizing the way we manage and virtualize APIs internally.”
Amplify is the only open, independent platform for managing and governing APIs across teams, the hybrid cloud, and third-party solutions. Axway’s “Open Everything” vision gives companies the flexibility and leverage to build brilliant customer experiences.
“To drive more consumption of APIs, we work to bring API creators and their consumers together,” added Donovan. “With a focus on reducing complexity and growing API adoption, we designed Axway Amplify to be an open platform that allows our customers to be in total control of all their APIs and events across gateways, vendors and deployments.”
Magic Quadrant™ reports are a culmination of rigorous, fact-based research in specific markets, providing a wide-angle view of the relative positions of the providers in markets where growth is high and provider differentiation is distinct. Providers are positioned into four quadrants: Leaders, Challengers, Visionaries and Niche Players. The research enables you to get the most from market analysis in alignment with your unique business and technology needs.
Click here to view a complimentary copy of the complete report.
1 Magic Quadrant for API Management, Shameen Pillai, Kimihiko Iijima, Mark O'Neill, John Santoro, Paul Dumas, Andrew Humphreys, Nicholas Carter, 11 October 2023
Gartner disclaimer
GARTNER is a registered trademark and service mark of Gartner and Magic Quadrant is a registered trademark of Gartner, Inc. and/or its affiliates in the U.S. and internationally and are used herein with permission. All rights reserved.
The report was published as Magic Quadrant for Application Services Governance for the year 2013 and 2015, as Magic Quadrant for Full Life Cycle API Management for 2016; 2019-2022, Axway was recognized as Axway (Vordel) in 2013.
Gartner does not endorse any vendor, product or service depicted in our research publications, and does not advise technology users to select only those vendors with the highest ratings or other designation. Gartner research publications consist of the opinions of Gartner research organization and should not be construed as statements of fact. Gartner disclaims all warranties, expressed or implied, with respect to this research, including any warranties of merchantability or fitness for a particular purpose.
About Axway
Axway enables enterprises to securely open everything by integrating and moving data across a complex world of new and old technologies. Axway’s API-driven B2B integration and MFT software, refined over 20 years, complements Axway Amplify, an open API management platform that makes APIs easier to discover and reuse across multiple teams, vendors, and cloud environments. Axway has helped over 11,000 businesses unlock the full value of their existing digital ecosystems to create brilliant experiences, innovate new services, and reach new markets. Learn more at axway.com
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20231016046652/en/
Contact information
Media Contact
Todd Holbrook
Tel. (480) 371-0113
tholbrook@axway.com
About Business Wire
Business Wire(c) 2018 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
QPS Holdings, LLC divests its Neuropharmacology Business Unit30.11.2023 14:15:00 CET | Press release
Today QPS Holdings, LLC (QPS) a leading drug development Contract Research Organization (CRO), announces an agreement to sell its Neuropharmacology business unit (QPS Neuropharmacology) to Scantox, a leading Nordic pre-clinical, GLP-accredited CRO. QPS Neuropharmacology, based in Grambach, Austria and focused on drug discovery, specializes in neurodegenerative diseases, rare diseases and mental disorders. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20231130940694/en/ QPS Neuropharmacology facility in Grambach, Austria. (Graphic: Business Wire) Founded in 1999, QPS Neuropharmacology has built a strong global reputation for high quality services that are deeply scientifically rooted and has an undisputed track-record of serving a loyal and broad customer base globally. This long history of developing expertise within neuropharmacology preclinical studies has contributed to strong year-on-year growth and positioned the organiz
ASICS Teams Up with BlueConic for Enhanced Personalization and Data Privacy Compliance30.11.2023 13:00:00 CET | Press release
ASICS, the global leader in athletic footwear and apparel, has selected pure-play customer data platform (CDP) BlueConic to reimagine the way it engages with customers. The move will empower the ASICS team to support a growing number of personalization projects while remaining compliant with consumer data privacy regulations around the globe. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20231128796155/en/ ASICS teams up with BlueConic to deliver personalization at scale. (Photo: Business Wire) With operations across the Americas, Europe, the Middle East, Asia, and Oceania, ASICS is best known for its sports apparel, shoes, equipment, and accessories for men, women, and children. The company acquired fitness app RunKeeper in 2016 for its potential as a one-on-one marketing channel. With a focus on increasing engagement and loyalty both within the app and across brands, channels, and regions, ASICS will use BlueConic to unify
LTIMindtree Partners with Metasphere to Deliver Smart Sewers Solutions30.11.2023 12:00:00 CET | Press release
LTIMindtree [NSE: LTIM, BSE: 540005], a global technology consulting and digital solutions company, announced that it has been selected as a strategic partner by Metasphere, a wastewater application specialist, to scale their Smart Sewers management platform. As a part of this engagement, LTIMindtree will transform Metasphere’s next-generation wastewater monitoring solution portfolio, and enable scalable delivery and platform to their customers. Metasphere, part of Grundfos, provides smart network management solutions to the global utility industry. The company helps customers prevent leaks and spills for a cleaner, greener world and has deployed more than 200K sensors for their customers worldwide. By leveraging cutting-edge technology, the company offers intelligent, innovative, all-in-one wastewater application solutions. These solutions provide full network visibility, performance and forecasting that reduce telemetry ownership cost for customers to manage time-critical remote asse
LatticeFlow Announces Intelligent Workflows for Eliminating AI Blind Spots30.11.2023 09:00:00 CET | Press release
LatticeFlow, the next-generation AI platform for enabling enterprise teams to build performant, safe, and trustworthy AI at scale, is proud to announce Intelligent Workflows, to help machine learning engineers proactively rectify errors and ensure the reliability and robustness of AI model performance in production. This cutting-edge technology aims to revolutionize the AI industry by addressing one of the most critical challenges faced by machine learning engineers today. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20231129791751/en/ (Graphic: Business Wire) With the proliferation of AI in business operations, the formidable task of seamlessly integrating high-performing AI models into real-world applications has grown increasingly critical. In particular, when dealing with large and complex datasets, ensuring production readiness for these models necessitates automation and a methodical approach to uncovering blind spots.
Results From Galderma’s Phase IIIb Trials Demonstrate Rapid and Long-Lasting Effect of RelabotulinumtoxinA on Crow’s Feet and Frown Lines30.11.2023 07:00:00 CET | Press release
Galderma announced today topline results from two phase IIIb trials investigating RelabotulinumtoxinA for the treatment of glabellar lines (GL – frown lines) and lateral canthal lines (LCL – crow’s feet). Both studies met their primary endpoints, demonstrating that RelabotulinumtoxinA, a novel liquid formulation botulinum toxin A, significantly improves both frown lines and crow’s feet, with a rapid onset of action as early as day one and long duration.1,2 “These results provide an additional layer of confidence in the long-lasting efficacy, speed and convenience of RelabotulinumtoxinA, which not only represents the innovation of our neuromodulator portfolio, but also demonstrates our commitment to responding to the real needs of healthcare professionals and patients.” BALDO SCASSELLATI SFORZOLINI, M.D., Ph.D. GLOBAL HEAD OF R&D GALDERMA 43QM2106 is a phase IIIb, randomized, double-blind, placebo-controlled trial to assess the aesthetic improvement and onset of action of Relabotulinumt